“I expect that we should grow at least in line with the market, David, which I expect I think it seems like the forecast here is mid to high teens.”

In context

“alists that we have out in the field that have shown their value to our customers right now. We've got both RF and PFA products. We've got all the elements, whether it's catheters, patches, etcetera. Introducer sheets, all of that you reference. And on top of that, we've got an LAA device, which is I would say is becoming pretty clear that if you want to be a leader in this space, you can't just look at having a PFA catheter. You've got to have the full portfolio including this device. Right now, it seems like 25% of LAA procedures are done concomitantly. So I think if you put all of that together, the portfolio that we've assembled combined with the resilience of what this team has done and how they've executed, I've got high expectations for this business this year. The team knows that. I expect that we should grow at least in line with the market, David, which I expect I think it seems like the forecast here is mid to high teens. So I think we're in a really good position and I'm excited to see the second part of the strategy that we put together three years ago. And we're really excited to kind of, you know, put that second part of that phase into action now. David Roman: Very helpful. Maybe just a follow-up on the guidance. I think we all know that you don't solve your guidance to meet short-term consensus. And you are committed to achieving your commitments. But as you've thought about putting together the outlook for 2026, considering some of the different variables that you faced over the past couple of quarters, like how did you think about risk adjusting the outlook? And maybe just help us think about the considerations in the guidance and maybe just your philosophy as you kind of put the outlook together h”